Tomohiko Ishikawa

975 total citations
35 papers, 817 citations indexed

About

Tomohiko Ishikawa is a scholar working on Molecular Biology, Oncology and Surgery. According to data from OpenAlex, Tomohiko Ishikawa has authored 35 papers receiving a total of 817 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 9 papers in Oncology and 7 papers in Surgery. Recurrent topics in Tomohiko Ishikawa's work include Salivary Gland Tumors Diagnosis and Treatment (5 papers), Ear and Head Tumors (4 papers) and Oral and Maxillofacial Pathology (4 papers). Tomohiko Ishikawa is often cited by papers focused on Salivary Gland Tumors Diagnosis and Treatment (5 papers), Ear and Head Tumors (4 papers) and Oral and Maxillofacial Pathology (4 papers). Tomohiko Ishikawa collaborates with scholars based in Japan, United States and China. Tomohiko Ishikawa's co-authors include Hisashi Hidaka, M. Saitoh, M Naka, H Hidaka, Yasuo Watanabe, Ryōji Kobayashi, Masatoshi Hagiwara, Kazumasa Sakurai, F. Kawamoto and Yukio Kimura and has published in prestigious journals such as Journal of Biological Chemistry, Cancer Research and Scientific Reports.

In The Last Decade

Tomohiko Ishikawa

34 papers receiving 803 citations

Peers

Tomohiko Ishikawa
Michael Mullin United States
Michael R. Dores United States
P. Daubas France
Christine Powers United States
Heide Plesken United States
Ewa Dziak Canada
Qing Lü China
Michael Mullin United States
Tomohiko Ishikawa
Citations per year, relative to Tomohiko Ishikawa Tomohiko Ishikawa (= 1×) peers Michael Mullin

Countries citing papers authored by Tomohiko Ishikawa

Since Specialization
Citations

This map shows the geographic impact of Tomohiko Ishikawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomohiko Ishikawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomohiko Ishikawa more than expected).

Fields of papers citing papers by Tomohiko Ishikawa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomohiko Ishikawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomohiko Ishikawa. The network helps show where Tomohiko Ishikawa may publish in the future.

Co-authorship network of co-authors of Tomohiko Ishikawa

This figure shows the co-authorship network connecting the top 25 collaborators of Tomohiko Ishikawa. A scholar is included among the top collaborators of Tomohiko Ishikawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomohiko Ishikawa. Tomohiko Ishikawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Koshizuka, Keiichi, Xingyu Wu, Kuniaki Sato, et al.. (2025). Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer. Cancer Research. 85(16). 3032–3051. 1 indexed citations
2.
Kimura, Masanobu, Yuriko Saiki, Tomohiko Ishikawa, et al.. (2025). Transcriptional regulation of ETV5 by mitogen-activated protein kinase via ETS-1 in human pancreatic cancer cells. Scientific Reports. 15(1). 12128–12128. 1 indexed citations
3.
Sato, Kuniaki, Farhoud Faraji, Rodolfo Daniel Cervantes‐Villagrana, et al.. (2025). Targeting YAP/TAZ-TEAD signaling as a therapeutic approach in head and neck squamous cell carcinoma. Cancer Letters. 612. 217467–217467. 6 indexed citations
4.
Goto, Yusuke, Keiichi Koshizuka, Toshinori Ando, et al.. (2024). A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC. Cancer Research Communications. 4(7). 1850–1862. 3 indexed citations
5.
Ishikawa, Tomohiko, Takenori Ogawa, Masahiro Shiihara, et al.. (2023). Salivary gland cancer organoids are valid for preclinical genotype-oriented medical precision trials. iScience. 26(5). 106695–106695. 3 indexed citations
6.
Ishikawa, Tomohiko, Shinichi Fukushige, Yuriko Saiki, et al.. (2023). Long Non-Coding RNAs Associated with Mitogen-Activated Protein Kinase in Human Pancreatic Cancer. Cancers. 15(1). 303–303. 6 indexed citations
7.
Ogawa, Takenori, Ayako Nakanome, Akira Ohkoshi, et al.. (2022). Investigation of the diversity of human papillomavirus 16 variants and L1 antigenic regions relevant for the prevention of human papillomavirus-related oropharyngeal cancer in Japan. Auris Nasus Larynx. 49(6). 1033–1041. 4 indexed citations
8.
Shiihara, Masahiro, Tomohiko Ishikawa, Yuriko Saiki, et al.. (2021). Development of a system combining comprehensive genotyping and organoid cultures for identifying and testing genotype-oriented personalised medicine for pancreatobiliary cancers. European Journal of Cancer. 148. 239–250. 16 indexed citations
9.
Ishikawa, Tomohiko, Takenori Ogawa, Ayako Nakanome, et al.. (2021). Whole exome sequencing and establishment of an organoid culture of the carcinoma showing thymus-like differentiation (CASTLE) of the parotid gland. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 478(6). 1149–1159. 12 indexed citations
10.
Ishida, Eiichi, Takenori Ogawa, Tomohiko Ishikawa, et al.. (2020). Management of adenoid cystic carcinoma of the head and neck: a single-institute study with over 25-year follow-up. Head & Face Medicine. 16(1). 14–14. 22 indexed citations
11.
Ogawa, Takenori, Tomohiko Ishikawa, Hajime Usubuchi, et al.. (2019). Parotid secretory carcinoma with high-grade transformation. Auris Nasus Larynx. 47(6). 1043–1048. 12 indexed citations
12.
Kurihara, Noriko, et al.. (2017). Gastric cancer metastatic to neck lipoma: a case report with imaging consideration. Skeletal Radiology. 47(4). 575–578. 5 indexed citations
13.
Ishikawa, Tomohiko, et al.. (1996). A new and potent calmodulin antagonist, HF-2035, which inhibits vascular relaxation induced by nitric oxide synthase. European Journal of Pharmacology. 299(1-3). 119–126. 6 indexed citations
14.
Hayashi, Toshio, Tomohiko Ishikawa, Masafumi Kuzuya, et al.. (1994). Chelation of copper reduces inhibition by oxidized lipoproteins of endothelium-dependent relaxation in porcine coronary arteries. Heart and Vessels. 9(6). 283–291. 2 indexed citations
15.
Terasawa, Motomu, Tomohiko Ishikawa, Hidenori Oguchi, et al.. (1993). A newly synthesized bifunctional inhibitor, W-77, enhances adriamycin activity against human ovarian carcinoma cells.. PubMed. 53(9). 2051–6. 10 indexed citations
16.
Hidaka, Hisashi & Tomohiko Ishikawa. (1992). Molecular pharmacology of calmodulin pathways in the cell functions. Cell Calcium. 13(6-7). 465–472. 28 indexed citations
17.
Watanabe, Yasuo, Ryōji Kobayashi, Tomohiko Ishikawa, & H Hidaka. (1992). Isolation and characterization of a calcium-binding protein derived from mRNA termed p9Ka, pEL-98, 18A2, or 42A by the newly synthesized vasorelaxant W-66 affinity chromatography. Archives of Biochemistry and Biophysics. 292(2). 563–569. 46 indexed citations
18.
Tani, Takeshi, Kazumasa Sakurai, Yukio Kimura, Tomohiko Ishikawa, & H Hidaka. (1992). Pharmacological manipulation of tissue cyclic AMP by inhibitors. Effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells.. PubMed. 25. 215–27. 34 indexed citations
19.
Hagiwara, Masatoshi, et al.. (1989). Specific inhibition of 40 k protein phosphorylation in platelet by a new antithrombotic agent, d-indobufen. Thrombosis Research. 54(5). 447–456. 2 indexed citations
20.
Hidaka, Hisashi, Masatoshi Hagiwara, Tomohiko Ishikawa, & M. Saitoh. (1989). Role of protein phosphorylation in Ca2+ regulated intracellular messenger systems.. PubMed. 5(1-2). 13–29. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026